326 related articles for article (PubMed ID: 26861970)
1. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Diamantidis MD; Neokleous N; Agapidou A; Vetsiou E; Manafas A; Fotiou P; Vlachaki E
Int J Hematol; 2016 May; 103(5):537-44. PubMed ID: 26861970
[TBL] [Abstract][Full Text] [Related]
2. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
3. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
4. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
5. Iron-chelation therapy with oral chelators in patients with thalassemia major.
Uygun V; Kurtoglu E
Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
[TBL] [Abstract][Full Text] [Related]
6. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
9. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Neufeld EJ
Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
[TBL] [Abstract][Full Text] [Related]
10. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
[No Abstract] [Full Text] [Related]
11. Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).
Vini D; Servos P; Drosou M
Eur J Haematol; 2011 Mar; 86(3):274-5. PubMed ID: 21198860
[No Abstract] [Full Text] [Related]
12. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
14. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
[TBL] [Abstract][Full Text] [Related]
18. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Haghpanah S; Zarei T; Zahedi Z; Karimi M
Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
[TBL] [Abstract][Full Text] [Related]
19. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]